Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Repligen Corporation has received a consensus rating of "Moderate Buy" from analysts, with four hold ratings and eight buy ratings among twelve research firms.
• The average twelve-month target price for Repligen's stock is $166.67, with projections ranging from a low of $130.00 to a high of $180.00.
• Institutional investors hold a significant portion of Repligen's stock, owning 97.64% of the company, indicating strong confidence in the firm's future prospects.

Repligen Corporation (NASDAQ:RGEN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $168.75.

RGEN has been the topic of several analyst reports. Evercore ISI upgraded Repligen from an "in-line" rating to an "outperform" rating and upped their price target for the company from $130.00 to $155.00 in a research report on Monday. Wells Fargo & Company reduced their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 30th. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price for the company. Jefferies Financial Group lowered their price objective on shares of Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a report on Friday, September 12th. Finally, Stephens raised Repligen to an "overweight" rating and set a $160.00 price objective on the stock in a research note on Tuesday, July 22nd.

Repligen Trading Up 3.0%

RGEN traded up $3.64 during trading on Friday, reaching $125.94. 758,926 shares of the stock traded hands, compared to its average volume of 754,600. The stock's 50-day moving average is $119.87 and its 200 day moving average is $126.06. Repligen has a 12 month low of $102.96 and a 12 month high of $182.52. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.09 billion, a PE ratio of -503.74, a P/E/G ratio of 2.25 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same quarter in the previous year, the company earned $0.40 EPS. The firm's revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Equities analysts anticipate that Repligen will post 1.72 earnings per share for the current year.

Insider Activity at Repligen

In other news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares of the company's stock, valued at $201,834. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Twin Tree Management LP purchased a new position in shares of Repligen in the 1st quarter valued at approximately $29,000. Hantz Financial Services Inc. raised its holdings in Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 293 shares in the last quarter. Signaturefd LLC lifted its position in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after buying an additional 128 shares during the period. Center for Financial Planning Inc. boosted its holdings in shares of Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after buying an additional 193 shares in the last quarter. Finally, UMB Bank n.a. grew its position in shares of Repligen by 99.4% in the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock worth $85,000 after buying an additional 332 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.